10-Q: MedWellAI Shifts to Healthcare, Faces Going Concern Doubts

MedWellAI, Inc. reported a strategic pivot to AI-driven healthcare and wellness, generating new revenue streams, but continues to face significant financial challenges and internal control weaknesses.

Summary

• MedWellAI, Inc. has strategically shifted its business focus from digital asset mining to AI-driven healthcare and wellness solutions, operating through two new segments: Pharmaceutical Products Distribution and Real Estate Development.
• Total revenue for the six months ended December 31, 2025, significantly increased to $1,075,806, up from $144,009 in the prior year, primarily driven by new product sales ($1,026,503) and rental income ($45,000).
• The company reported a net loss attributable to shareholders of $(939,397) for the six months ended December 31, 2025, a substantial improvement from the $(1,889,958) loss in the same period last year.
• Despite revenue growth and reduced net loss, the company's current liabilities exceeded current assets by $7,513,736 as of December 31, 2025, and it has an accumulated deficit of $89,613,277, raising substantial doubt about its ability to continue as a going concern.
• Cash used in operating activities improved to $(255,749) for the six months ended December 31, 2025, compared to $(461,576) in the prior year, but remains negative.
• The company's digital asset mining operations were discontinued as of June 7, 2024, and online sales of health and wellness products are no longer pursued due to regulatory hurdles.
• Series C and D preferred stock were consolidated into a single Series C Convertible Preferred Stock, resulting in a $241,918 loss on exchange and the retirement of $2,133,081 in accrued and unpaid dividends.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly concerning filing due to the explicit 'going concern' warning, significant working capital deficit, and identified material weaknesses in internal controls, despite the strategic pivot and revenue growth in new segments.

Positives

• Total revenue for the six months ended December 31, 2025, increased significantly to $1,075,806, up from $144,009 in the prior year, indicating successful establishment of new revenue streams.
• Product sales, a new segment, generated $1,026,503 in revenue for the six months ended December 31, 2025, demonstrating strong initial performance in GLP medications distribution.
• Rental income, another new segment, contributed $45,000 in revenue for the six months ended December 31, 2025.
• Net loss attributable to shareholders decreased substantially to $(939,397) for the six months ended December 31, 2025, from $(1,889,958) in the prior year, indicating improved operational efficiency or reduced non-recurring losses.
• Cash used in operating activities improved to $(255,749) for the six months ended December 31, 2025, from $(461,576) in the prior year, showing a reduction in operational cash burn.
• The company successfully retired $2,133,081 in accrued and unpaid preferred stock dividends through a share exchange agreement.

Negatives

• The company's current liabilities of $7,678,166 significantly exceeded its current assets of $164,430 by $7,513,736 as of December 31, 2025.
• An accumulated deficit of $89,613,277 as of December 31, 2025, indicates a history of substantial losses.
• Cash balance decreased significantly to $137,503 as of December 31, 2025, from $401,310 as of June 30, 2025.
• Commission revenues decreased sharply to $2,702 for the six months ended December 31, 2025, from $133,272 in the prior year.
• Online sales revenues decreased to $1,601 for the six months ended December 31, 2025, from $10,737 in the prior year, with the company having exited this segment due to regulatory hurdles.
• A note payable of $500,000 with BHP Capital NY, Inc. remains in default due to nonpayment before its maturity date of January 15, 2023.
• Amounts due to related party (accrued salary to Mr. Rubakh) increased to $463,882 as of December 31, 2025, from $209,419 as of June 30, 2025.
• A loss on exchange of Series C & D preferred shares of $241,918 was recognized during the six months ended December 31, 2025.

Risks

• The company has reported recurring net losses from operations and used net cash in operating activities, and its current liabilities exceed current assets by $7,513,736, raising substantial doubt about its ability to continue as a going concern.
• The ability to reach and maintain a successful level of operations is dependent on raising capital through debt and/or equity markets, with no assurances of success.
• Disclosure controls and procedures were not effective as of December 31, 2025.
• Material weaknesses in internal control over financial reporting include the lack of independent board members, absence of an audit committee financial expert, issues with segregation of duties in a small company, and the lack of a written policy for related party transaction approval.
• The company incurs increased costs as a publicly traded company, including significant legal, accounting, and compliance expenses, and struggles to afford director and officer liability insurance.
• The company's note payable of $500,000 is in default, incurring an 18% per annum default interest rate (reduced to 10% effective April 1, 2024).

Future Outlook

The company's business focus is on AI-driven healthcare and wellness solutions, specifically through its MedWell USA subsidiary, which operates a B2B e-commerce platform for distributing pharmaceutical products (GLP medications), and its MedWell Facilities subsidiary, which develops real estate opportunities for healthcare providers. Management plans to address the structure of the Board of Directors and discuss adding an audit committee during the fiscal year ending June 30, 2026.

Management Comments

• Management believes that the plans, objectives, expectations, and prospects reflected in or suggested by forward-looking statements are reasonable, but acknowledge risks, uncertainties, and other factors that may cause actual results to differ materially.
• The ability of the Company to reach and maintain a successful level of operations is dependent on the execution of management's plans, which include the raising of capital through the debt and/or equity markets, until such time that funds provided by operations are sufficient to fund working capital requirements.

Industry Context

StockSavvy.ai notes that MedWellAI's strategic pivot from digital asset mining to AI-driven healthcare and wellness aligns with broader industry trends emphasizing technological integration in health and the growing market for GLP medications. The establishment of a B2B e-commerce platform for pharmaceutical distribution and a real estate development arm for wellness facilities positions the company to capitalize on these trends. However, the company's exit from online sales due to regulatory hurdles highlights the complex and evolving regulatory landscape within the digital health sector.

Corporate Governance

Legal Proceedings

• The company is not currently involved in any litigation that is believed to have a material adverse effect on its financial condition or results of operations.

Related Party Transactions

• Steve Rubakh, the sole executive officer and Board member, earns an annual salary of $250,000 and quarterly cash bonuses of $100,000.
• Amounts due to related party, consisting of accrued salary to Mr. Rubakh, totaled $463,882 as of December 31, 2025, an increase from $209,419 as of June 30, 2025.

Stakeholder Impact

• Shareholders face significant risk due to the 'going concern' doubt, substantial accumulated deficit, and negative working capital, which could lead to further dilution if capital raises occur or a loss of investment if the company fails.
• Creditors, particularly BHP Capital NY, Inc. with a note in default, face uncertainty regarding repayment given the company's financial instability.
• Employees, especially Mr. Rubakh, have significant accrued compensation due, which may be at risk if the company's financial situation does not improve.
• Customers and suppliers in the pharmaceutical distribution and real estate segments may face operational disruptions or payment delays if the company's financial challenges persist.

Next Steps

• Management plans to address the structure of the Board of Directors during the fiscal year ending June 30, 2026.
• Management plans to discuss adding an audit committee during the fiscal year ending June 30, 2026.
• The company needs to raise capital through debt and/or equity markets to fund working capital requirements and continue operations.

Key Dates

Recommendation

The filing presents a dire financial situation with an explicit 'going concern' warning, a substantial working capital deficit of over $7.5 million, and a growing accumulated deficit of nearly $90 million. While the strategic shift to healthcare and new revenue streams are positive developments, they are overshadowed by fundamental financial instability, negative cash flow from operations, and critical internal control weaknesses. The company's ability to survive is dependent on future capital raises, which carry significant dilution risk. For a seasoned investor, these factors indicate a high probability of further share price decline and potential loss of capital, warranting a strong sell recommendation.

Keywords

AI-driven healthcare, wellness solutions, pharmaceutical distribution, GLP medications, weight loss, diabetes management, real estate development, facilities management, SEC filing, 10-Q, going concern, internal controls, corporate governance, financial results